BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research(摘要待生成)
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook - Zacks Investment Research
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook - Zacks Investment Research(摘要待生成)
Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Bristol Myers Squibb's Growth Portfolio revenue grew 12% to $7.7 billion in the third quarter. [[fact:fact-3nj3q7a7d]] Total revenue was $13.1 billion, up 7% from the prior-year quarter. [[fact:fact-ra3p4crmq]] Earnings per share were $1.05 GAAP and $1.35 adjusted; adjusted EPS fell 17% from $1.63. [[fact:fact-x0t0r1tft]] The company raised its 2026 revenue guidance to $49.75 billion to $50.25 billion. [[fact:fact-eq7uvypvj]]
Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript
Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript(摘要待生成)
Bristol Myers lifts sales outlook as newer drugs drive growth
Bristol Myers lifts sales outlook as newer drugs drive growth(摘要待生成)
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie reported FY 2025 revenue of about $61.2 billion, up roughly 8.6% year over year. [[fact:fact-4gvtj6rto]] Bristol Myers Squibb reported FY 2025 revenue of about $48.2 billion, down 0.2% year over year. [[fact:fact-95u3rgr2o]] Skyrizi and Rinvoq together accounted for roughly 42% of AbbVie's total net revenue in 2025. [[fact:fact-hoa1rnq6p]] The article forecasts Bristol Myers Squibb's current fiscal-year revenue to rise 3% to $49.9 billion, but this projection is unconfirmed. [[fact:fact-pagal02qc]] It also forecasts Bristol Myers Squibb's net income to rise more than 40% to $11.2 billion, another unconfirmed projection. [[fact:fact-vqlcrohbl]] Bristol Myers Squibb faces a revived $6.7 billion lawsuit related to its Celgene acquisition. [[fact:fact-byyh3ckyl]]
Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.
Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.(摘要待生成)
Bristol Myers Squibb director Julia Haller sells $240,578 in stock
Bristol Myers Squibb director Julia Haller sells $240,578 in stock(摘要待生成)